Sanofi has shared positive results from a late-stage study of its investigational BTK inhibitor, tolebrutinib, in patients ...

It was very disconcerting. For a fraction of a second, as I sat in a plush, modern boardroom, there across the table from me sat a magnificent giraffe, slowly ruminating as its small horns and large ...

Novo Nordisk and NanoVation Therapeutics have entered into a multi-year partnership worth $600m to advance genetic medicines ...

Merck & Co – known as MSD outside the US and Canada – and Daiichi Sankyo have announced that a late-stage trial of patritumab deruxtecan in non-small cell lung cancer (NSCLC) met its primary endpoint ...

To successfully navigate a rare disease pathway, it is necessary to understand the interdependency of clinical, regulatory and commercial branches, as well as their different and sometimes competing ...

Merck/Daiichi Sankyo’s ADC candidate shows promise in phase 3 lung cancer trial - PMLiVE ...

Researchers from the Institute of Cancer Research (ICR) have found that prostate cancer patients with high levels of a specific protein have significantly poorer outcomes compared to those without.

Dive into a comprehensive exploration of the latest trends and cutting-edge strategies in medical publication planning. Our exclusive webinar series, starting next week, offers a deep dive into the ...

Merck & Co – known as MSD outside the US and Canada – has shared positive overall survival (OS) results from a late-stage ...

Daiichi Sankyo’s Vanflyta (quizartinib) has been recommended by the National Institute for Health and Care Excellence (NICE) for certain cases of acute myeloid leukaemia (AML). The drug has been ...

Merck & Co – known as MSD outside the US and Canada – has received approval from the US Food and Drug Administration (FDA) for the use of Keytruda (pembrolizumab) in malignant pleural mesothelioma.